ticlopidine has been researched along with Sensitivity and Specificity in 96 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 9.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "Unresponsiveness to clopidogrel or aspirin has been reported in patients with acute coronary syndrome (ACS)." | 9.13 | Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. ( Einav, Y; Fefer, P; Hod, H; Lubetsky, A; Matetzky, S; Savion, N; Shenkman, B; Varon, D, 2008) |
| "We sought to evaluate the long-term cost-effectiveness of clopidogrel for up to one year after an acute coronary syndrome (ACS) without ST-segment elevation." | 9.11 | Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. ( Caro, J; Culler, S; Gabriel, S; Lamy, A; Mahoney, EM; Weintraub, WS; Yuan, Y; Yusuf, S, 2005) |
| "Clopidogrel resistance(CR)is found in non-cardioembolic ischemic stroke (NCIS) patients." | 7.80 | VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. ( Huang, L; Lai, X; Li, W; Xiong, Z; Xu, A; Zhang, S, 2014) |
| " prasugrel plus bivalirudin in patients with ST-segment elevation myocardial infarction." | 5.22 | Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). ( Braun, D; Braun, S; Hausleiter, J; Kastrati, A; Knipper, A; Massberg, S; Mehilli, J; Orban, M; Petzold, T; Schulz, S; Sibbing, D, 2016) |
| " Subjects with coronary artery disease treated with aspirin were randomly assigned to clopidogrel 75 mg daily or prasugrel 10 mg daily for 7 days." | 5.19 | Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. ( Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Price, MJ, 2014) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 5.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "Unresponsiveness to clopidogrel or aspirin has been reported in patients with acute coronary syndrome (ACS)." | 5.13 | Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. ( Einav, Y; Fefer, P; Hod, H; Lubetsky, A; Matetzky, S; Savion, N; Shenkman, B; Varon, D, 2008) |
| "Low-response to the P2Y12 adenosine diphosphate (ADP)-receptor antagonist clopidogrel was suggested to correspond to a higher incidence of stent thrombosis (ST)." | 5.12 | The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. ( Blindt, R; de Taeye, A; Hoffmann, R; Kelm, M; Kiefer, P; Müller, R; Stellbrink, K; Weber, C; Yagmur, E, 2007) |
| "We sought to evaluate the long-term cost-effectiveness of clopidogrel for up to one year after an acute coronary syndrome (ACS) without ST-segment elevation." | 5.11 | Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. ( Caro, J; Culler, S; Gabriel, S; Lamy, A; Mahoney, EM; Weintraub, WS; Yuan, Y; Yusuf, S, 2005) |
| "Enhanced platelet inhibition by clopidogrel decreases the risk of ischemic events but carries a risk for a concomitant increase in bleeding." | 4.87 | Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Christ, G; Herkner, H; Huber, K; Jilma, B; Kubica, J; Schrör, K; Siller-Matula, JM, 2011) |
| "Patients with acute coronary syndromes and patients who undergo coronary stent implantation frequently receive dual antiplatelet therapy with aspirin and a thienopyridine." | 4.85 | Monitoring platelet function to reduce the risk of ischemic and bleeding complications. ( Price, MJ, 2009) |
| " The ACTIVE-W study was a noninferiority comparison of the combination of clopidogrel and acetylsalicylic acid versus oral anticoagulant among patients with atrial fibrillation." | 4.84 | Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. ( Cairns, JA; Gent, M; Hirsh, J; Marler, J; Pogue, J; Pritchett, EL; Wittes, J; Wyse, DG, 2008) |
| "Clopidogrel resistance(CR)is found in non-cardioembolic ischemic stroke (NCIS) patients." | 3.80 | VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. ( Huang, L; Lai, X; Li, W; Xiong, Z; Xu, A; Zhang, S, 2014) |
| " Phenotyping of platelet response to clopidogrel was a better predictor of stent thrombosis than genotyping." | 3.78 | Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. ( Delle-Karth, G; Grzybowski, T; Huber, K; Jilma, B; Kozinski, M; Kubica, J; Lang, IM; Linkowska, K; Maurer, G; Neunteufl, T; Siller-Matula, JM, 2012) |
| "Clopidogrel should be initiated as soon as possible in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) except those who urgently require coronary artery bypass grafting (CABG)." | 3.77 | An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. ( Ebina, T; Endo, M; Hibi, K; Ishikawa, T; Iwahashi, N; Kimura, K; Kosuge, M; Maejima, N; Morita, S; Okada, K; Umemura, S, 2011) |
| "Platelet hyperreactivity in MEA might be a better risk predictor for stent thrombosis than the assessment of the specific clopidogrel effect with the VASP phosphorylation assay." | 3.76 | Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. ( Christ, G; Delle-Karth, G; Huber, K; Jilma, B; Lang, IM; Siller-Matula, JM, 2010) |
| " An increased risk of thrombosis after coronary stenting for ACS patients treated with aspirin and clopidogrel has been linked to high platelet reactivity and, for certain patients, poor drug response." | 3.76 | VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. ( Bidet, A; Coste, P; Jais, C; Jakubowski, J; Nurden, A; Nurden, P; Puymirat, E, 2010) |
| "In patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS), identification of left main and/or 3-vessel disease (LM/3VD) is crucial for deciding whether to initiate early treatment with clopidogrel, which can increase the risk of surgical bleeding." | 3.75 | Early, accurate, non-invasive predictors of left main or 3-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. ( Ebina, T; Hashiba, K; Hibi, K; Kimura, K; Kiyokuni, M; Komura, N; Kosuge, M; Morita, S; Nakayama, N; Umemura, S, 2009) |
| "Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
| " The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel." | 3.73 | A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005) |
| "Subdural hematomas are amenable to risk stratification analysis." | 1.46 | A Decision Instrument to Identify Isolated Traumatic Subdural Hematomas at Low Risk of Neurologic Deterioration, Surgical Intervention, or Radiographic Worsening. ( Borczuk, P; Ornam, JV; Pruitt, P, 2017) |
| "Fibrinogen ≥345 mg/dl was significantly associated with both CK-MB-defined (p = 0." | 1.39 | Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. ( Ang, L; Ilapakurti, M; Lee, MS; Mahmud, E; Palakodeti, V; Thani, KB, 2013) |
| "A rapid, simple, and easy method for the simultaneous determination of clopidogrel and aspirin from bulk material and dosage formulations in the presence of meloxicam as internal standard has been developed." | 1.37 | Simultaneous determination of clopidogrel and aspirin by RP-HPLC from bulk material and dosage formulations using multivariate calibration technique. ( Ali, KA; Arayne, MS; Nawaz, M; Sultana, N, 2011) |
| "The present study describes a new analytical approach for the detection and characterization of chemically reactive metabolites using glutathione ethyl ester (GSH-EE) as the trapping agent in combination with hybrid triple quadrupole linear ion trap mass spectrometry." | 1.35 | Screening and characterization of reactive metabolites using glutathione ethyl ester in combination with Q-trap mass spectrometry. ( Fitch, WL; Wen, B, 2009) |
| " HCPR as measured with the novel INNOVANCE P2Y cartridge was associated with clinical determinants such as BMI, female gender, impaired LVEF (left ventricular ejection fraction), renal failure and dosing of clopidogrel." | 1.35 | The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. ( Berg, JM; Bouman, HJ; Elsenberg, EH; Hackeng, CM; van de Wal, RM; van Werkum, JW; Verheugt, FW; Zomer, AC, 2009) |
| " The developed assay method was applied to a pharmacokinetic study in human volunteers after oral administration of clopidogrel at a dose of 150 mg." | 1.34 | Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. ( Shin, BS; Yoo, SD, 2007) |
| " The method was successfully applied to the pharmacokinetic study of the two different polymorphs of clopidogrel bisulfate in Wistar rat." | 1.33 | Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. ( Barot, D; Lohray, VB; Mohan, PR; Sharma, K; Singh, SS, 2005) |
| "Ticlopidine was used as internal standard and the total run time of analysis was about 12 min." | 1.33 | Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. ( Dalvandi, A; Jalalizadeh, H; Kebriaee-Zadeh, A; Shekarchi, M; Souri, E, 2006) |
| "Aspirin was both less expensive and more effective than clopidogrel in post-myocardial infarction patients." | 1.32 | Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. ( Owens, DK; Schleinitz, MD; Weiss, JP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.13) | 18.2507 |
| 2000's | 41 (42.71) | 29.6817 |
| 2010's | 52 (54.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tian, KP | 1 |
| Guan, J | 1 |
| Cai, LL | 1 |
| Li, YR | 1 |
| Deng, XL | 1 |
| Liu, QY | 1 |
| Zheng, BX | 1 |
| Cong, YL | 1 |
| Lyngby, JG | 1 |
| Court, MH | 1 |
| Lee, PM | 1 |
| Koltai, K | 1 |
| Kesmarky, G | 1 |
| Feher, G | 1 |
| Tibold, A | 1 |
| Toth, K | 1 |
| Pruitt, P | 1 |
| Ornam, JV | 1 |
| Borczuk, P | 1 |
| Nalawade, V | 1 |
| Vora, A | 1 |
| Patti, G | 1 |
| Mangiacapra, F | 1 |
| Ricottini, E | 1 |
| Cannatà, A | 1 |
| Cavallari, I | 1 |
| Vizzi, V | 1 |
| D'Ambrosio, A | 1 |
| Dicuonzo, G | 1 |
| Di Sciascio, G | 1 |
| Spiliopoulos, S | 1 |
| Pastromas, G | 1 |
| Katsanos, K | 1 |
| Kitrou, P | 1 |
| Karnabatidis, D | 1 |
| Siablis, D | 1 |
| Zhang, L | 1 |
| Cui, G | 1 |
| Li, Z | 1 |
| Wang, H | 1 |
| Ding, H | 1 |
| Wang, DW | 1 |
| Abtan, J | 1 |
| Silvain, J | 2 |
| Kerneis, M | 1 |
| O'Connor, SA | 1 |
| Barthélémy, O | 2 |
| Vignalou, JB | 1 |
| Beygui, F | 2 |
| Brugier, D | 1 |
| Collet, JP | 2 |
| Montalescot, G | 2 |
| Scott, SA | 1 |
| Tan, Q | 1 |
| Baber, U | 1 |
| Yang, Y | 1 |
| Martis, S | 1 |
| Bander, J | 1 |
| Kornreich, R | 1 |
| Hulot, JS | 2 |
| Desnick, RJ | 1 |
| Glenn, JR | 1 |
| Dovlatova, N | 1 |
| White, AE | 1 |
| Dhillon, K | 1 |
| Heptinstall, S | 1 |
| Fox, SC | 1 |
| Price, MJ | 2 |
| Baker, BA | 1 |
| Jakubowski, JA | 1 |
| Li, W | 2 |
| Heiselman, DE | 1 |
| Angiolillo, DJ | 3 |
| Karon, BS | 1 |
| Tolan, NV | 1 |
| Koch, CD | 1 |
| Wockenfus, AM | 1 |
| Miller, RS | 1 |
| Lingineni, RK | 1 |
| Pruthi, RK | 1 |
| Chen, D | 1 |
| Jaffe, AS | 1 |
| Koh, YY | 1 |
| Kim, HH | 1 |
| Choi, DH | 1 |
| Lee, YM | 1 |
| Ki, YJ | 1 |
| Kang, SH | 1 |
| Park, G | 1 |
| Chung, JW | 1 |
| Chang, KS | 1 |
| Hong, SP | 1 |
| Baysal, E | 1 |
| Çetin, M | 1 |
| Yaylak, B | 1 |
| Altntaş, B | 1 |
| Altndağ, R | 1 |
| Adyaman, Ş | 1 |
| Altaş, Y | 1 |
| Kaya, İ | 1 |
| Sevuk, U | 1 |
| Zhang, S | 1 |
| Lai, X | 1 |
| Xiong, Z | 1 |
| Xu, A | 2 |
| Huang, L | 1 |
| Plicner, D | 1 |
| Mazur, P | 1 |
| Hymczak, H | 1 |
| Stoliński, J | 1 |
| Litwinowicz, R | 1 |
| Drwiła, R | 1 |
| Undas, A | 1 |
| Alfredsson, J | 1 |
| Lindahl, TL | 1 |
| Gustafsson, KM | 1 |
| Janzon, M | 1 |
| Jonasson, L | 1 |
| Logander, E | 1 |
| Nilsson, L | 1 |
| Swahn, E | 1 |
| Hua, W | 1 |
| Lesslie, M | 1 |
| Hoffman, BT | 1 |
| Binns, C | 1 |
| Mulvana, D | 1 |
| Gielen, CL | 1 |
| Bruggemans, EF | 1 |
| Stijnen, T | 1 |
| Eikenboom, J | 1 |
| Tavilla, G | 1 |
| Brand, A | 1 |
| Klautz, RJ | 1 |
| Jovin, IS | 1 |
| Ebisu, KA | 1 |
| Oprea, AD | 1 |
| Brandt, CA | 1 |
| Natale, D | 1 |
| Finta, LA | 1 |
| Dziura, J | 1 |
| Wackers, FJ | 1 |
| Braun, D | 1 |
| Knipper, A | 1 |
| Orban, M | 1 |
| Sibbing, D | 1 |
| Petzold, T | 1 |
| Braun, S | 1 |
| Schulz, S | 1 |
| Hausleiter, J | 1 |
| Kastrati, A | 1 |
| Mehilli, J | 1 |
| Massberg, S | 1 |
| Morofuji, T | 1 |
| Inaba, S | 1 |
| Hitsumoto, T | 1 |
| Takahashi, K | 1 |
| Aisu, H | 1 |
| Higashi, H | 1 |
| Saito, M | 1 |
| Ohshima, K | 1 |
| Ikeda, S | 1 |
| Hamada, M | 1 |
| Sumimoto, T | 1 |
| Kim, CH | 1 |
| Hwang, G | 1 |
| Kwon, OK | 1 |
| Ban, SP | 1 |
| Chinh, ND | 1 |
| Tjahjadi, M | 1 |
| Oh, CW | 1 |
| Bang, JS | 1 |
| Kim, T | 1 |
| Janssen, PW | 1 |
| Bergmeijer, TO | 1 |
| Godschalk, TC | 1 |
| Le, TT | 1 |
| Breet, NJ | 1 |
| Kelder, JC | 1 |
| Hackeng, CM | 2 |
| Ten Berg, JM | 1 |
| Wen, B | 2 |
| Fitch, WL | 1 |
| Mueller, T | 1 |
| Dieplinger, B | 1 |
| Poelz, W | 1 |
| Haltmayer, M | 1 |
| McKellar, SH | 1 |
| Thompson, JL | 1 |
| Garcia-Rinaldi, RF | 1 |
| Macdonald, RJ | 1 |
| Sundt, TM | 1 |
| Schaff, HV | 1 |
| Siller-Matula, JM | 4 |
| Lang, I | 1 |
| Christ, G | 3 |
| Jilma, B | 4 |
| Fayed, AS | 1 |
| Weshahy, SA | 1 |
| Shehata, MA | 1 |
| Hassan, NY | 1 |
| Pauwels, J | 1 |
| Hoogmartens, J | 1 |
| Van Schepdael, A | 1 |
| Gremmel, T | 1 |
| Steiner, S | 1 |
| Seidinger, D | 1 |
| Koppensteiner, R | 1 |
| Panzer, S | 1 |
| Kopp, CW | 1 |
| Jennings, LK | 1 |
| Kosuge, M | 2 |
| Ebina, T | 2 |
| Hibi, K | 2 |
| Morita, S | 2 |
| Komura, N | 1 |
| Hashiba, K | 1 |
| Kiyokuni, M | 1 |
| Nakayama, N | 1 |
| Umemura, S | 2 |
| Kimura, K | 2 |
| Esposito, RA | 1 |
| Manjunath Swamy, J | 1 |
| Kamath, N | 1 |
| Radha Shekar, AK | 1 |
| Srinivas, NR | 1 |
| Kristjansson, F | 1 |
| Elsenberg, EH | 1 |
| van Werkum, JW | 1 |
| van de Wal, RM | 1 |
| Zomer, AC | 1 |
| Bouman, HJ | 1 |
| Verheugt, FW | 1 |
| Berg, JM | 1 |
| Malmström, RE | 1 |
| Ostergren, J | 1 |
| Jørgensen, L | 1 |
| Hjemdahl, P | 1 |
| Poppe, T | 1 |
| Singal, B | 1 |
| Cowen, M | 1 |
| Srikanth, A | 1 |
| Goraya, TY | 1 |
| Lang, IM | 2 |
| Delle-Karth, G | 2 |
| Huber, K | 3 |
| Bidet, A | 1 |
| Jais, C | 1 |
| Puymirat, E | 1 |
| Coste, P | 1 |
| Nurden, A | 1 |
| Jakubowski, J | 1 |
| Nurden, P | 1 |
| Kang, HS | 1 |
| Kwon, BJ | 1 |
| Kim, JE | 1 |
| Han, MH | 1 |
| Meimoun, P | 1 |
| Boulanger, J | 1 |
| Luycx-Bore, A | 1 |
| Zemir, H | 1 |
| Elmkies, F | 1 |
| Malaquin, D | 1 |
| Doutrelan, L | 1 |
| Tribouilloy, C | 1 |
| Serra, H | 1 |
| Bronze, Mdo R | 1 |
| Simplício, AL | 1 |
| Delavenne, X | 1 |
| Basset, T | 1 |
| Zufferey, P | 1 |
| Malouk, N | 1 |
| Laporte, S | 1 |
| Mismetti, P | 1 |
| Pena, A | 1 |
| Bellemain-Appaix, A | 1 |
| Cayla, G | 1 |
| Bal Dit Sollier, C | 1 |
| Berge, N | 1 |
| Boval, B | 1 |
| Dubar, M | 1 |
| Drouet, L | 1 |
| Schrör, K | 1 |
| Kubica, J | 2 |
| Herkner, H | 1 |
| Koessler, J | 1 |
| Kobsar, AL | 1 |
| Rajkovic, MS | 1 |
| Schafer, A | 1 |
| Flierl, U | 1 |
| Pfoertsch, S | 1 |
| Bauersachs, J | 1 |
| Steigerwald, U | 1 |
| Rechner, AR | 1 |
| Walter, U | 1 |
| Endo, M | 1 |
| Maejima, N | 1 |
| Iwahashi, N | 1 |
| Okada, K | 1 |
| Ishikawa, T | 1 |
| Turner, D | 1 |
| Raftery, J | 1 |
| Cooper, K | 1 |
| Fairbank, E | 1 |
| Palmer, S | 1 |
| Ward, S | 1 |
| Ara, R | 1 |
| Sultana, N | 1 |
| Arayne, MS | 1 |
| Ali, KA | 1 |
| Nawaz, M | 1 |
| Tuffal, G | 1 |
| Roy, S | 1 |
| Lavisse, M | 1 |
| Brasseur, D | 1 |
| Schofield, J | 1 |
| Delesque Touchard, N | 1 |
| Savi, P | 1 |
| Bremond, N | 1 |
| Rouchon, MC | 1 |
| Hurbin, F | 1 |
| Sultan, E | 1 |
| Kukin, M | 1 |
| Messerli, FH | 1 |
| McGlasson, DL | 1 |
| Shah, AD | 1 |
| Fritsma, GA | 1 |
| Buchan, BW | 1 |
| Peterson, JF | 1 |
| Cogbill, CH | 1 |
| Anderson, DK | 1 |
| Ledford, JS | 1 |
| White, MN | 1 |
| Quigley, NB | 1 |
| Jannetto, PJ | 1 |
| Ledeboer, NA | 1 |
| Connolly, SJ | 1 |
| Eikelboom, JW | 1 |
| Ng, J | 1 |
| Hirsh, J | 2 |
| Yusuf, S | 2 |
| Pogue, J | 2 |
| de Caterina, R | 1 |
| Hohnloser, S | 1 |
| Hart, RG | 1 |
| Peer, CJ | 1 |
| Spencer, SD | 1 |
| VanDenBerg, DA | 1 |
| Pacanowski, MA | 1 |
| Horenstein, RB | 1 |
| Figg, WD | 1 |
| Neunteufl, T | 1 |
| Kozinski, M | 1 |
| Maurer, G | 1 |
| Linkowska, K | 1 |
| Grzybowski, T | 1 |
| Vidali, M | 1 |
| Rolla, R | 1 |
| Parrella, M | 1 |
| Cassani, C | 1 |
| Manzini, M | 1 |
| Portalupi, MR | 1 |
| Serino, R | 1 |
| Prando, MD | 1 |
| Bellomo, G | 1 |
| Pergolini, P | 1 |
| Zhang, HZ | 1 |
| Yu, LH | 1 |
| Kim, MH | 1 |
| Jang, J | 1 |
| Lim, J | 1 |
| Chang, K | 1 |
| Kim, Y | 1 |
| Kim, M | 1 |
| Park, HI | 1 |
| Kim, J | 1 |
| Shin, S | 1 |
| Ang, L | 1 |
| Thani, KB | 1 |
| Ilapakurti, M | 1 |
| Lee, MS | 1 |
| Palakodeti, V | 1 |
| Mahmud, E | 1 |
| Elsinghorst, PW | 1 |
| Nomura, S | 1 |
| Takahashi, N | 1 |
| Inami, N | 1 |
| Kajiura, T | 1 |
| Yamada, K | 1 |
| Nakamori, H | 1 |
| Tsuda, N | 1 |
| Schleinitz, MD | 2 |
| Weiss, JP | 1 |
| Owens, DK | 1 |
| Borges, NC | 1 |
| Mendes, GD | 1 |
| Borges, A | 1 |
| Oliveira, SE | 1 |
| Barrientos-Astigarraga, RE | 1 |
| Nucci, GD | 1 |
| Dyszkiewicz-Korpanty, AM | 1 |
| Frenkel, EP | 2 |
| Sarode, R | 2 |
| Heidenreich, PA | 1 |
| Weintraub, WS | 1 |
| Mahoney, EM | 1 |
| Lamy, A | 1 |
| Culler, S | 1 |
| Yuan, Y | 1 |
| Caro, J | 1 |
| Gabriel, S | 1 |
| Singh, SS | 1 |
| Sharma, K | 1 |
| Barot, D | 1 |
| Mohan, PR | 1 |
| Lohray, VB | 1 |
| Craft, RM | 1 |
| Chavez, JJ | 1 |
| Snider, CC | 1 |
| Muenchen, RA | 1 |
| Carroll, RC | 1 |
| Komatsu, T | 1 |
| Tamai, Y | 1 |
| Takami, H | 1 |
| Yamagata, K | 1 |
| Fukuda, S | 1 |
| Munakata, A | 1 |
| Graff, J | 1 |
| Harder, S | 1 |
| Moore, RK | 1 |
| Lowe, R | 1 |
| Grayson, AD | 1 |
| Morris, JL | 1 |
| Perry, RA | 1 |
| Stables, RH | 1 |
| Souri, E | 1 |
| Jalalizadeh, H | 1 |
| Kebriaee-Zadeh, A | 1 |
| Shekarchi, M | 1 |
| Dalvandi, A | 1 |
| Danikiewicz, W | 1 |
| Swist, M | 1 |
| Shin, BS | 1 |
| Yoo, SD | 1 |
| Paniccia, R | 1 |
| Antonucci, E | 1 |
| Gori, AM | 1 |
| Marcucci, R | 1 |
| Poli, S | 1 |
| Romano, E | 1 |
| Valente, S | 1 |
| Giglioli, C | 1 |
| Fedi, S | 1 |
| Gensini, GF | 1 |
| Abbate, R | 1 |
| Prisco, D | 1 |
| Sbrana, S | 1 |
| Della Pina, F | 1 |
| Rizza, A | 1 |
| Buffa, M | 1 |
| De Filippis, R | 1 |
| Gianetti, J | 1 |
| Clerico, A | 1 |
| Dyszkiewicz-Korpanty, A | 1 |
| Olteanu, H | 1 |
| Bernardo, E | 1 |
| Sabaté, M | 1 |
| Jimenez-Quevedo, P | 1 |
| Costa, MA | 1 |
| Palazuelos, J | 1 |
| Hernández-Antolin, R | 1 |
| Moreno, R | 1 |
| Escaned, J | 1 |
| Alfonso, F | 2 |
| Bañuelos, C | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Macaya, C | 1 |
| Fernandez-Ortiz, A | 1 |
| Blindt, R | 1 |
| Stellbrink, K | 1 |
| de Taeye, A | 1 |
| Müller, R | 1 |
| Kiefer, P | 1 |
| Yagmur, E | 1 |
| Weber, C | 1 |
| Kelm, M | 1 |
| Hoffmann, R | 1 |
| Cairns, JA | 1 |
| Wittes, J | 1 |
| Wyse, DG | 1 |
| Gent, M | 1 |
| Marler, J | 1 |
| Pritchett, EL | 1 |
| Shenkman, B | 1 |
| Matetzky, S | 1 |
| Fefer, P | 1 |
| Hod, H | 1 |
| Einav, Y | 1 |
| Lubetsky, A | 1 |
| Varon, D | 1 |
| Savion, N | 1 |
| Linnemann, B | 1 |
| Schwonberg, J | 1 |
| Mani, H | 1 |
| Prochnow, S | 1 |
| Lindhoff-Last, E | 1 |
| Ma, L | 1 |
| Nelson, SD | 1 |
| Zhu, M | 1 |
| Bahrami, G | 1 |
| Mohammadi, B | 1 |
| Sisakhtnezhad, S | 1 |
| FitzGerald, GA | 1 |
| Salonia, J | 1 |
| Pannu, R | 1 |
| Andraws, R | 1 |
| Dal Bo, L | 1 |
| Verga, F | 1 |
| Marzo, A | 1 |
| Ambrosoli, L | 1 |
| Poli, A | 1 |
| Róna, K | 1 |
| Ary, K | 1 |
| Gachályi, B | 1 |
| Klebovich, I | 1 |
| Lagorce, P | 1 |
| Perez, Y | 1 |
| Ortiz, J | 1 |
| Necciari, J | 1 |
| Bressolle, F | 1 |
| Calverley, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of Platelet Reactivity in Peripheral Arterial Disease Patients Undergoing Percutaneous Angioplasty on Mid-term Outcomes[NCT04165629] | 450 participants (Anticipated) | Observational | 2020-01-01 | Recruiting | |||
| Clinical Impact of High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures. The PRECLOP Study (Platelet REsponsiveness to CLOpidogrel Treatment After Peripheral Angioplasty or Stenting)[NCT01744613] | 100 participants (Actual) | Observational [Patient Registry] | 2010-01-31 | Completed | |||
| Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling of Unruptured Intracranial Aneurysms: A Prospective Randomized Multicenter Trial[NCT05257824] | Phase 4 | 528 participants (Anticipated) | Interventional | 2022-06-23 | Recruiting | ||
| Platelet Function in Resuscitated Patients[NCT02914795] | 99 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).[NCT01012544] | Phase 4 | 187 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)[NCT01184300] | Phase 2/Phase 3 | 200 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome[NCT01994941] | Phase 4 | 133 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00243178] | Phase 3 | 6,706 participants (Actual) | Interventional | 2003-07-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02914795)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Non-resuscitated Myocardial Infarction | 0 |
| Resuscitated Myocardial Infarction | 3 |
Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is. (NCT02914795)
Timeframe: day 3
| Intervention | AU*min (Median) |
|---|---|
| Non-resuscitated Myocardial Infarction | 109 |
| Resuscitated Myocardial Infarction | 253.8 |
10 reviews available for ticlopidine and Sensitivity and Specificity
| Article | Year |
|---|---|
Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications.
Topics: Blood Platelets; Humans; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitor | 2017 |
Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hemo | 2009 |
Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, | 2009 |
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.
Topics: Alleles; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 Enzyme System; Humans; Myocardial Ischem | 2010 |
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr | 2011 |
Quantitative determination of clopidogrel and its metabolites in biological samples: a mini-review.
Topics: Chromatography, Liquid; Clopidogrel; Humans; Sensitivity and Specificity; Tandem Mass Spectrometry; | 2013 |
Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clinical Tri | 2008 |
Translational therapeutics at the platelet vascular interface. Summary.
Topics: Angina, Unstable; Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Drug Evalu | 2008 |
Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Confidence Int | 2008 |
Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Plate | 2001 |
15 trials available for ticlopidine and Sensitivity and Specificity
| Article | Year |
|---|---|
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; | 2014 |
Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Drug Combinations; Female; Human | 2015 |
Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel: results from Assessing Platelet Activity in Coronary Heart Disease (APACHE).
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Platelet Aggregation; Platelet Cou | 2015 |
Stopping antiplatelet medication before coronary artery bypass graft surgery: is there an optimal timing to minimize bleeding?
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; D | 2015 |
Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy).
Topics: Antithrombins; Clopidogrel; Drug Therapy, Combination; Female; Heparin; Hirudins; Humans; Male; Midd | 2016 |
Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Card | 2009 |
Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Double-Blind Me | 2010 |
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial | 2011 |
Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.
Topics: Aged; Analysis of Variance; Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Sele | 2004 |
Ticlopidine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study.
Topics: Chromatography, High Pressure Liquid; Humans; Platelet Aggregation Inhibitors; Sensitivity and Speci | 2004 |
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Electrocardiography; Fema | 2005 |
Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clopidogrel; Elective Surgical Procedures; Humans; Platelet | 2005 |
The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cell Adhesion Molecules; Clopi | 2007 |
Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Clopidogrel; | 2008 |
High-performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in human serum: Application to a bioequivalence study.
Topics: Acetonitriles; Adult; Carboxylic Acids; Chromatography, High Pressure Liquid; Clopidogrel; Drug Stab | 2008 |
71 other studies available for ticlopidine and Sensitivity and Specificity
| Article | Year |
|---|---|
[Evaluation of PFA P2Y assay in monitoring platelet function in elderly patients with cardiovascular disease receiving clopidogrel treatment].
Topics: Biological Assay; Blood Coagulation Tests; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Hu | 2016 |
Validation of a method for quantitation of the clopidogrel active metabolite, clopidogrel, clopidogrel carboxylic acid, and 2-oxo-clopidogrel in feline plasma.
Topics: Animals; Cats; Chromatography, High Pressure Liquid; Clopidogrel; Reproducibility of Results; Sensit | 2017 |
A Decision Instrument to Identify Isolated Traumatic Subdural Hematomas at Low Risk of Neurologic Deterioration, Surgical Intervention, or Radiographic Worsening.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Cohort Studies; Decision Su | 2017 |
Box-Behnken design directed optimization for sensitivity assessment of anti-platelet drugs.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Clopidogrel; Models, Chemical; Plat | 2019 |
Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Biomarkers; C-Reactive Protein; Clopi | 2013 |
Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity.
Topics: Aged; Blood Platelets; Clopidogrel; Disease-Free Survival; Endovascular Procedures; Female; Humans; | 2013 |
Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity.
Topics: Aged; Blood Platelets; Clopidogrel; Disease-Free Survival; Endovascular Procedures; Female; Humans; | 2013 |
Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity.
Topics: Aged; Blood Platelets; Clopidogrel; Disease-Free Survival; Endovascular Procedures; Female; Humans; | 2013 |
Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity.
Topics: Aged; Blood Platelets; Clopidogrel; Disease-Free Survival; Endovascular Procedures; Female; Humans; | 2013 |
Comparison of high-resolution melting analysis, TaqMan Allelic discrimination assay, and sanger sequencing for Clopidogrel efficacy genotyping in routine molecular diagnostics.
Topics: Adult; Alleles; Clopidogrel; Female; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Mul | 2013 |
Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cell Adhesion Molecules; Cell Separation; Clopidogrel | 2013 |
An allele-specific PCR system for rapid detection and discrimination of the CYP2C19∗4A, ∗4B, and ∗17 alleles: implications for clopidogrel response testing.
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Base Sequence; Case-Control Studies; Clopidogrel; Coronary A | 2013 |
'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
Topics: Adenosine; Adenosine Diphosphate; Alprostadil; Biomarkers, Pharmacological; Blood Platelets; Buclade | 2014 |
Precision and reliability of 5 platelet function tests in healthy volunteers and donors on daily antiplatelet agent therapy.
Topics: Arachidonic Acid; Aspirin; Clopidogrel; Female; Healthy Volunteers; Humans; Male; Platelet Aggregati | 2014 |
Relation between the Change in Mean Platelet Volume and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Mean P | 2015 |
Roles of the red cell distribution width and neutrophil/lymphocyte ratio in predicting thrombolysis failure in patients with an ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Er | 2015 |
VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Ischemia; Cell Adhesion Molecules; China; Clopidog | 2014 |
Development of a sensitive and fast UHPLC-MS/MS method for determination of clopidogrel, clopidogrel acid and clopidogrel active metabolite H4 in human plasma.
Topics: Blood Chemical Analysis; Calibration; Chromatography, High Pressure Liquid; Clopidogrel; Humans; Mic | 2015 |
The influence of clopidogrel on ischemia diagnosed by myocardial perfusion stress testing.
Topics: Cardiotonic Agents; Clopidogrel; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Ischem | 2016 |
Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Humans; Japan; Male; | 2016 |
P2Y
Topics: Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Embolization, Therapeutic; Female; H | 2017 |
The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions.
Topics: Aged; Area Under Curve; Blood Platelets; Clopidogrel; Female; Follow-Up Studies; Hematocrit; Humans; | 2017 |
Screening and characterization of reactive metabolites using glutathione ethyl ester in combination with Q-trap mass spectrometry.
Topics: Acetaminophen; Amodiaquine; Carbamazepine; Glutathione; Humans; Imipramine; Mass Spectrometry; Metab | 2009 |
Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel | 2009 |
Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine.
Topics: Administration, Oral; Animals; Aspirin; Bioprosthesis; Clopidogrel; Dalteparin; Disease Models, Anim | 2008 |
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Case-Control Studies; Cell Adhesion | 2008 |
Separation and determination of clopidogrel and its impurities by capillary electrophoresis.
Topics: Buffers; Clopidogrel; Cyclodextrins; Drug Contamination; Electricity; Electrophoresis, Capillary; Et | 2009 |
Early, accurate, non-invasive predictors of left main or 3-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Corona | 2009 |
Invited commentary.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Graft Survival; Hum | 2009 |
Sensitivity enhancement and matrix effect evaluation during summation of multiple transition pairs-case studies of clopidogrel and ramiprilat.
Topics: Chromatography, Liquid; Clopidogrel; Humans; Ramipril; Sensitivity and Specificity; Tandem Mass Spec | 2010 |
The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Cells, | 2009 |
Poor performance with a platelet counting technique to monitor clopidogrel inhibitory effects in the point-of-care setting.
Topics: Clopidogrel; Humans; Platelet Aggregation Inhibitors; Platelet Count; Point-of-Care Systems; Reprodu | 2010 |
Is it possible to safely administer early a loading dose of clopidogrel before coronary angiography to patients who are candidates for percutaneous coronary intervention?
Topics: Acute Coronary Syndrome; Adult; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coho | 2009 |
Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; | 2010 |
VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
Topics: Adult; Aged; Aged, 80 and over; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfil | 2010 |
Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications.
Topics: Aged; Blood Coagulation Tests; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial | 2010 |
Non-invasive coronary flow reserve after successful primary angioplasty for acute anterior myocardial infarction is an independent predictor of left ventricular adverse remodelling.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Echocardiography; Female; Fractional Flow Rese | 2010 |
Simultaneous determination of clopidogrel and its carboxylic acid metabolite by capillary electrophoresis.
Topics: Carboxylic Acids; Clopidogrel; Electrophoresis, Capillary; Hydrogen-Ion Concentration; Least-Squares | 2010 |
Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite.
Topics: Chromatography, High Pressure Liquid; Clopidogrel; Humans; Molecular Structure; Reference Values; Re | 2010 |
The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Biological Assay; Biomarkers; Blood Platele | 2011 |
An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Biomarkers; Clopidogrel; Coronary Angiograp | 2011 |
The CHD challenge: comparing four cost-effectiveness models.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Humans; Hydrox | 2011 |
Simultaneous determination of clopidogrel and aspirin by RP-HPLC from bulk material and dosage formulations using multivariate calibration technique.
Topics: Aspirin; Calibration; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatograph | 2011 |
An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; CHO Cells; Chromatography, High Pressure Liquid; Cl | 2011 |
Wireless pulmonary artery haemodynamic monitoring.
Topics: Anticoagulants; Aspirin; Clopidogrel; Electrodes, Implanted; Equipment Design; Female; Heart Failure | 2011 |
Ability of the INNOVANCE PFA P2Y system to detect clopidogrel-induced ADP receptor blockade in preangiocath individuals.
Topics: Adult; Angiography; Blood Coagulation; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diagno | 2011 |
Evaluation of a microarray-based genotyping assay for the rapid detection of cytochrome P450 2C19 *2 and *3 polymorphisms from whole blood using nanoparticle probes.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Hematologic Tests; H | 2011 |
A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma.
Topics: Chromatography, High Pressure Liquid; Clopidogrel; Drug Stability; Humans; Reproducibility of Result | 2012 |
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Austria; Blood Platelets; Cardi | 2012 |
Role of the laboratory in monitoring patients receiving dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Clinical Laboratory Techniques; Clopidogrel; D | 2012 |
Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: a comparison between citrate and hirudin.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; A | 2013 |
A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Drug Resistance; Female; Human | 2012 |
Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
Topics: Aged; Blood Platelets; C-Reactive Protein; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB | 2013 |
Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Fibrinolytic Agents; Humans; Markov Chains; Middle Aged | 2004 |
Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods.
Topics: Adolescent; Adult; Aspirin; Blood Platelets; Child; Clopidogrel; Diagnostic Tests, Routine; Electric | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study.
Topics: Animals; Carboxylic Acids; Chromatography, High Pressure Liquid; Clopidogrel; Drug Stability; Male; | 2005 |
Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures.
Topics: Adult; Aspirin; Bleeding Time; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration | 2005 |
Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents.
Topics: Abciximab; Adenosine Monophosphate; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Do | 2005 |
A study comparing the incidence and predictors of creatine kinase MB and troponin T release after coronary angioplasty. Does Clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention?
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Cohort Studies; Coronary Disease; Creatine | 2007 |
Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study.
Topics: Adult; Carboxylic Acids; Chromatography, High Pressure Liquid; Clopidogrel; Humans; Male; Platelet A | 2006 |
The fragmentation reactions of anti-platelet drugs: clopidogrel and ticlopidine.
Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Clopidogrel; Platelet Aggregation Inh | 2007 |
Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study.
Topics: Adult; Chromatography, Liquid; Clopidogrel; Humans; Male; Platelet Aggregation Inhibitors; Reproduci | 2007 |
Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2007 |
Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Adhesion Molec | 2008 |
Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100).
Topics: Adult; Aged; Clopidogrel; Female; Hematologic Tests; Humans; Male; Middle Aged; Optics and Photonics | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure.
Topics: Adenosine Diphosphate; Cardiovascular Diseases; Clopidogrel; Flow Cytometry; Humans; Platelet Aggreg | 2007 |
Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Algorithms; Arachidonic Acid; Aspirin; Calibr | 2008 |
High-throughput screening and characterization of reactive metabolites using polarity switching of hybrid triple quadrupole linear ion trap mass spectrometry.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Clo | 2008 |
Common blood thinners: what are the differences?
Topics: Anticoagulants; Aspirin; Clopidogrel; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; | 2008 |
Determination of ticlopidine in human plasma by high-performance liquid chromatography and ultraviolet absorbance detection.
Topics: Acetonitriles; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Methanol; S | 1995 |
[Validity of a liquid chromatographic (HPLC) method for the determination of ticlopidine in human plasma].
Topics: Chromatography, High Pressure Liquid; Humans; Indicators and Reagents; Reproducibility of Results; S | 1997 |
Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography-mass spectrometry.
Topics: Calibration; Carboxylic Acids; Clopidogrel; Gas Chromatography-Mass Spectrometry; Humans; Platelet A | 1998 |